← All trials
NCT06475989
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 13, 2024
- Primary completion
- Sep 30, 2030
- Completion date
- Sep 30, 2030
- First posted
- Jun 26, 2024
- Last posted
- Jun 26, 2024
- Enrollment
- 264
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ECOG-ACRIN Cancer Research GroupLead sponsor
- ECOG-ACRIN Cancer Research GroupOfficial
- National Cancer Institute (NCI)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.